Publications by authors named "M Teitelbaum"
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.
Lancet Microbe
November 2024
Article Synopsis
- rVSVΔG-ZEBOV-GP is a vaccine that helps protect people from the Ebola virus and is the first one to be officially approved for this purpose.
- This study wanted to see how well a booster shot given 18 months after the first vaccine dose helped keep the immune response strong for a longer time.
- Healthy adults who might be at risk of exposure to Ebola participated in the trial, and the results measured their antibody levels 36 months after the first vaccination to compare those who got the booster with those who did not.
Article Synopsis
- Children with chronic conditions often have unique health care needs that may not be fully addressed through current treatment practices focused on family and patient preferences.
- A scoping review was conducted to analyze interventions aimed at enhancing family-centered care for these children by examining relevant studies published between January 2019 and August 2020.
- The review found 61 interventions, primarily using quasiexperimental and randomized controlled trial designs, with key focuses on improving communication, involving families in care decisions, and increasing access to health services.
Article Synopsis
- Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA) are rare vascular tumors in children, and this study aimed to identify effective first-line therapies due to the lack of clinical trials.
- The study included 159 patients, revealing high treatment response rates (>70%) to both sirolimus and vincristine, with no significant differences in effectiveness over time.
- The findings suggest personalized treatment approaches are essential, as both medications showed similar outcomes, and the low mortality rate (1.3%) indicates improved management of these tumors.
The effects of locally applied zinc chloride (ZnCl ) on early and late-stage parameters of fracture healing were evaluated in a diabetic rat model. Type 1 Diabetes has been shown to negatively impact mechanical parameters of bone as well as biologic markers associated with bone healing. Zinc treatments have been shown to reverse those outcomes in tests of nondiabetic and diabetic animals.
View Article and Find Full Text PDFEfficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.
Ann Intern Med
September 2022
Background: Ensovibep (MP0420) is a designed ankyrin repeat protein, a novel class of engineered proteins, under investigation as a treatment of SARS-CoV-2 infection.
Objective: To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared with standard care alone.
Design: Double-blind, randomized, placebo-controlled, clinical trial.